gastrointestinal

News

Ironwood crashes down as FDA seeks new phase 3 trial

Shares in Ironwood fell by a third after it revealed the FDA is insisting on a new phase 3 trial of its short bowel syndrome therapy apraglutide.

News

Vanda slams FDA rejection of gastroparesis drug

The FDA has declined to approve Vanda Pharma's tradipitant for delayed gastric emptying (gastroparesis), prompting a furious response from the company.

Digital

The new frontier of microbiome-directed human health

The microbiome is ever more frequently spoken about of late, and so the pharmaphorum podcast invited Leo Grady, founder and CEO of Jona, to speak about at-home personal microbiome profiling

News

Ironwood wagers $1bn on VectivBio’s phase 3 readout

Gastrointestinal disease specialist Ironwood Pharma has agreed a $1 billion deal to buy VectivBio and its drug candidate for short bowel syndrome (SBS), betting on positiv

News

After coeliac fail, 9 Meters plots phase 3 in short bowel sy...

Two weeks after reporting disappointing results for its lead coeliac disease therapy, 9 Meters Biopharma will draw some comfort from a mid-stage trial of its candidate for short bowel syndr

News